Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next-generation Sequencing: Slowly Moving towards the $1,000 Genome

This article was originally published in Start Up

Executive Summary

Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.

You may also be interested in...



The How And When Of Applying Sequencing To Clinical Diagnostics

Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.

GnuBio: Whole Genome Sequencing for $30

Say goodbye to the $1000 genome, and even the $100 genome. Thanks to a fledging start-up out of Harvard, there may be an even lower near-term benchmark. Speaking at a meeting in Boston, GnuBio described technology for doing whole-genome sequencing for as little as $30 a pop using an interation of microdroplet technology already in commercial use, out of the same lab.

Financings Of The Fortnight: Cardiome's Reticence The Exception During Busy Spate Of Deals

Highlighting this edition is a pair of privately held genomic sequencing companies that raised funds in new venture rounds.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091206

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel